Independent editorial reviews of tirzepatide telehealth providers — transparent methodology, verified data, monthly updates.
GLP1OneTelehealth.com exists to help patients make informed decisions when choosing among the dozens of telehealth providers now offering tirzepatide and other GLP-1 medications. The category has grown rapidly, marketing claims are loud, and meaningful comparison requires looking at clinical model, pharmacy disclosure, total cost, and patient safety practices side-by-side. We do that work and publish the results.
GLP1OneTelehealth is an independent editorial publication. Provider scores are determined exclusively by our published 100-point methodology covering clinical model, pharmacy disclosure, pricing structure, included services, state coverage, and patient-facing safety. Scoring is reproducible by readers using the same evidence sources.
We maintain editorial referral relationships with some providers reviewed on this site. These relationships are disclosed on every page and on individual provider reviews. They do not influence editorial scoring; they support the cost of the editorial review process. Editorial decisions are firewalled from business relationships.
GLP1OneTelehealth.com may receive compensation from some of the providers featured on this site when readers visit linked sites or sign up for programs. These compensation arrangements influence which providers may appear and in what order they may be displayed within marketing-driven sections, but they do not influence the editorial score itself, which is determined by our published methodology.
Our top-ranked provider — NexLife — earns the #1 position based on our scoring criteria: flat-rate pricing transparency, dual 503A and 503B pharmacy disclosure, MD/DO clinical supervision, Care360 coaching included, and coverage in all 50 states. Reasonable readers can apply different weighting to these criteria and reach different conclusions; we encourage you to read our full methodology.
GLP1OneTelehealth content is reviewed on rolling cycles:
Last full editorial review: May 15, 2026.
All clinical and regulatory facts cite peer-reviewed publications indexed on PubMed, FDA prescribing information, FDA drug shortage list announcements, and published clinical practice guidelines. Provider-specific facts are sourced from provider-published material, public press releases, and where appropriate, primary regulatory filings.
We do not invent statistics. We do not publish clinical recommendations. Content is informational and references public data. Treatment decisions belong to a licensed clinician with access to the patient's full medical history.
Editorial questions, factual corrections, partnership inquiries, or general feedback: glponetelehealth@gmail.com
For provider review requests or methodology questions, please include the provider name and your specific question in the subject line.
GLP1OneTelehealth.com is published independently. Site operated since January 2026. Content licensed for editorial use only — please contact us for republication permissions.